

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/US04/041374

International filing date: 13 December 2004 (13.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/528,892  
Filing date: 11 December 2003 (11.12.2003)

Date of receipt at the International Bureau: 31 January 2005 (31.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1274599

# UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*January 19, 2005*


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/528,892

FILING DATE: *December 11, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/41374

Certified by



Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office





18304 U.S.PTO

Please type a plus sign (+) inside this box → 

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a provisional filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EU 861356146 US

INVENTOR(S)					
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)			
Jack	Elias	Woodbridge, CT			
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
<b>TITLE OF THE INVENTION (280 characters max)</b>					
CCR5 blockage in emphysema					
Direct all correspondence to: <b>CORRESPONDENCE ADDRESS</b> <input type="checkbox"/> Customer Number <input style="width: 150px; height: 15px; border: 1px solid black; margin-left: 10px;" type="text"/> → <input style="width: 150px; height: 15px; border: 1px solid black; margin-left: 10px;" type="text"/> OR <input style="width: 150px; height: 15px; border: 1px solid black; margin-left: 10px;" type="text"/> <b>Type Customer Number here</b>					
<input checked="" type="checkbox"/> Firm or Individual Name	Yale University, Office of Cooperative Research				
Address	433 Temple Street				
Address					
City	New Haven	State	CT	ZIP	06511
Country	USA	Telephone	(203) 436-8096	Fax	(203) 436-8086
<b>ENCLOSED APPLICATION PARTS (check all that apply)</b>					
<input checked="" type="checkbox"/> Specification Number of Pages	<input type="text" value="2"/>	<input type="checkbox"/> CD(s), Number	<input style="width: 100px; height: 15px; border: 1px solid black;" type="text"/>		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets	<input type="text" value="26"/>	<input type="checkbox"/> Other (specify)	<input style="width: 100px; height: 15px; border: 1px solid black;" type="text"/>		
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
<b>METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT</b>					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input type="checkbox"/> A check or money order is enclosed to cover the filing fees <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <input type="text" value="25-0110"/>				FILING FEE AMOUNT (\$) <input type="text" value="80.00"/>	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. <input type="checkbox"/> No. <input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____ <b>NHLBI HL 66571</b>					

Respectfully submitted,

SIGNATURE

Date TYPED or PRINTED NAME   
TELEPHONE REGISTRATION NO.  
(if appropriate)  
Docket Number:**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

7548  
60/528892  
U.S.PTO  
121103

121103

**Subject:** CCR 5

**From:** Jack Elias <jack.elias@yale.edu>  
**Date:** Wed, 10 Dec 2003 18:54:59 -0500  
**To:** John Puziss <john.puziss@yale.edu>  
**CC:** kathy bertier <kathleen.bertier@yale.edu>

John

Kathy from my office will be sending you a zip with a set of powerpoint slides demonstrating the effects of antibody and genetic neutralization/ablation of CCR 5 in the IL-13 and gamma interferon mice. (They are too big to send by E-mail). As you can see, both interventions decreased emphysema and inflammation (Th2-like in the case of IL-13 and Th1-like in the case of gamma). In the case of the IL-13 mice the elimination of CCR5 also increased survival. Other items to note are the ability of the CCR5 based interventions to

1. decrease TNF production
2. decrease IL-13 induced apoptosis (assessed by TUNEL staining)
3. decrease gamma interferon and IL-13-induced chemokine production including MCP-1, MIP-1alpha, MIP-1 beta, KC, IP-10

Thus we believe CCR 5 blockade can diminish IL-13 (Th2) and gamma interferon (Th1) induced inflammation, remodeling, emphysema and apoptosis

Call me if you have questions

Jack

# Methods

---

CC10-IL-13 transgenic mice

CC10-rtTA-IL-13 transgenic mice

CC10-rtTA-IFN- $\gamma$  transgenic mice

Anti - CCR5 monoclonal antibody

CCR5KO mice

From Jackson Lab

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Stimulation of CCR5 gene expression by IL-13, IL-4 and  
gamma interferon *in vivo*




# Protocol for anti-CCR5 treatment

---



Anti-CCR5 antibody given every other day by i.p.  
500 $\mu$ g per time.

Day 1      d2      d3      d4      d5      d6      d7      d8      d9      d10      d11




## Effect of anti-CCR5 on IL-13-induced increase in lung volume


	-	+	-	+	+	+	+
Control IgG	+	-	-	-	-	-	-
Anti-CCR5	-	-	+	-	-	-	-
Dox	+	+	+	+	+	+	+
IL-13	-	-	-	-	-	-	-




# Effect of anti-CCR5 on IL-13-induced Inflammation




# Effect of anti-CCR5 on IL-13 induced emphysema




## Chord Length of Ind IL-13 mice: Effect of anti-CCR5




## Effect of anti-CCR5 on the levels of BAL IL-13



## Lung volume change of INF- $\gamma$ mice after anti-CCR5 treatment



# BAL total cell count of IFN- $\gamma$ mice after anti-CCR5 treatment




# Effect of anti-CCR5 on emphysema in CC10-IFN- $\gamma$ Lungs

Ab control


Anti-CCR5

IFN- $\gamma$   
(-)


IFN- $\gamma$   
(+)




## Effect of anti-CCR 5 on BAL IFN- $\gamma$ Levels




# Survival Days of CCI--IL-13 Mice with WT and Null Mutant CCR5 Loci




## Role of CCR5 in IL-13-induced increase in lung size




## Role of CCR5 in IL-13-induced BAL Inflammation




## Role of CCR5 in IFN- $\gamma$ -induced increase in lung size





# Role of CCR5 in IFN- $\gamma$ -induced inflammation





# Role of CCR5 in IFN- $\gamma$ -induced emphysema







# Role of CCR5 in IFN- $\gamma$ stimulation of KC and IP-10




# Effect of anti-CCR5 on IL-13 induced emphysema




# Percentage of TUNEL (+) cells on IL-13 Mouse Lung




## Role of CCR5 in IL-13/ IFN- $\gamma$ induced TNF- $\alpha$ production



## Role of CCR5 in IL-4-induced increase in lung size



## Role of CCR5 in IL-4-induced BAL inflammation



# TUNEL Staining in IL-13 Mouse Lung

Treatment: Control IgG

Anti-CCR5


IL-13  
(-)



IL-13  
(+)




## Role of CCR5 in CC10-IL-4 Lung



## Role of CCR5 in IL-13-induced lung phenotype

CCR5 (+/+)                          CCR5 KO



IL-13  
(-)

IL-13  
(+)